admin – Page 3030 – Get News Story

Advanced Renal Cell Carcinoma Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “ Advanced Renal Cell Carcinoma Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of advanced renal cell carcinoma, historical and forecasted epidemiology as well as the advanced renal cell carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Advanced Renal Cell Carcinoma Market Share @ Advanced Renal Cell Carcinoma Market Outlook

Key Takeaways from the Advanced Renal Cell Carcinoma Market Report

In June 2025, Karie Runcie announced a study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
In June 2025, Bristol-Myers Squibb announced a study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
According to findings, renal cell carcinoma accounts for 90% of all kidney cancers.
One in three people with renal cell carcinoma receive a diagnosis at the metastatic stage.
RCC predominantly affects the male population, with men being significantly more susceptible as compared to women.
There are several types of RCC, but 75% of patients have a type called clear cell.
Several factors can be attributed to an increased risk of RCC, including smoking, obesity, and high blood pressure and having a family history of certain conditions, such as von Hippel-Lindau disease, a rare genetic multi-system disorder characterized by abnormal blood vessel growth.
RCC is difficult to detect in its early stages, and >30% patients with RCC have metastatic, or advanced, cancer at the time of diagnosis, meaning the cancer cells have spread beyond the kidney to other parts of the body.
The leading Advanced Renal Cell Carcinoma Companies such as CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics and others.
Promising Advanced Renal Cell Carcinoma Pipeline Therapies such as Bevacizumab, Atezolizumab, TQB2450, Anlotinib, Sunitinib, HB0025, Botensilimab, Balstilimab, Ipilimumab and others.

Stay ahead in the Advanced Renal Cell Carcinoma Therapeutics Market with DelveInsight’s Strategic Report @ Advanced Renal Cell Carcinoma Treatment Market

Advanced Renal Cell Carcinoma Epidemiology Segmentation in the 7MM

Advanced Renal Cell Carcinoma Incident Cases of Kidney Cancer
Advanced Renal Cell Carcinoma Incident Cases
Advanced Renal Cell Carcinoma Subtype-specific Incident
Advanced Renal Cell Carcinoma Stage-specific Incident Cases
Advanced Renal Cell Carcinoma Gender-specific Incident Cases
Advanced Renal Cell Carcinoma Diagnosed and Treated Cases

Download the report to understand which factors are driving Advanced Renal Cell Carcinoma Epidemiology trends @ Advanced Renal Cell Carcinoma Prevalence

Marketed Advanced Renal Cell Carcinoma Drugs

KEYTRUDA (pembrolizumab): Merck

It is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. In April 2019, the FDA approved pembrolizumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma

WELIREG (belzutifan): Merck

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). HIF-2α is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia. Under normal oxygen levels, HIF-2α is targeted for ubiquitin-proteasomal degradation by VHL protein. In December 2023, the US FDA WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma.

Emerging Advanced Renal Cell Carcinoma Drugs

Zanzalintinib (XL092) + Nivolumab: Exelixis/BMS

Zanzalintinib represents a next‐generation oral TKI designed to inhibit the activity of receptor tyrosine kinases associated with cancer growth and spread. These include VEGF receptors, MET, AXL, and MER, which play crucial roles in various cellular functions and pathological processes such as oncogenesis, metastasis, and tumor angiogenesis. Zanzalintinib builds upon Exelixis’ extensive experience with cabozantinib, their flagship medicine, aiming to enhance key characteristics like pharmacokinetic half‐life.

Savolitinib + Durvalumab: AstraZeneca/HUTCHMED

Savolitinib is an investigational inhibitor of the mesenchymal–epithelial transition factor, or MET receptor tyrosine kinase, an enzyme that has been shown to function abnormally in many types of solid tumors. We designed savolitinib through chemical structure modification to specifically address kidney toxicity, the primary issue that halted the development of several other selective MET inhibitors

To learn more about Advanced Renal Cell Carcinoma Treatment guidelines, visit @ Advanced Renal Cell Carcinoma Clinical Trials Assessment

Advanced Renal Cell Carcinoma Companies

CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics and others.

Advanced Renal Cell Carcinoma Market Outlook

Advanced Renal Cell Carcinoma companies, including Exelixis, Bristol-Myers Squibb (BMS), AstraZeneca, and HUTCHMED, are actively evaluating their lead candidates at various stages of clinical development, focusing on the treatment of advanced renal cell carcinoma. The Advanced Renal Cell Carcinoma market outlook appears promising, driven by these companies’ efforts to innovate and expand the therapeutic arsenal. As these investigational therapies progress through clinical trials, they hold the potential to significantly improve patient outcomes and address unmet needs in advanced renal cell carcinoma management. The competitive landscape is poised for dynamic growth, with advancements in targeted therapies, immunotherapies, and combination treatments, ultimately aiming to enhance survival rates and quality of life for patients.

Learn more about the FDA-approved drugs for Advanced Renal Cell Carcinoma @ Drugs for Advanced Renal Cell Carcinoma Treatment

Scope of the Advanced Renal Cell Carcinoma Market Report

Coverage- 7MM
Study Period- 2020-2034
Advanced Renal Cell Carcinoma Companies- CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics and others.
Advanced Renal Cell Carcinoma Pipeline Therapies- Bevacizumab, Atezolizumab, TQB2450, Anlotinib, Sunitinib, HB0025, Botensilimab, Balstilimab, Ipilimumab and others.
Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma Market Drivers and Barriers
Advanced Renal Cell Carcinoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Advanced Renal Cell Carcinoma (RCC)

4. Key Events

5. Advanced Renal Cell Carcinoma Epidemiology and Market Forecast Methodology

6. Advanced Renal Cell Carcinoma Market Overview at a Glance

7. Disease Background and Overview: RCC

8. Advanced Renal Cell Carcinoma Treatment and Management

9. Epidemiology and Patient Population of RCC in Latin America and Canada

10. Advanced Renal Cell Carcinoma Patient Journey

11. Key Endpoints in Advanced RCC

12. Marketed Advanced Renal Cell Carcinoma Therapies

13. Emerging Advanced Renal Cell Carcinoma Therapies

14. Advanced RCC: the US, EU4& the UK and Japan

15. Advanced Renal Cell Carcinoma Unmet Needs

16. Advanced Renal Cell Carcinoma SWOT Analysis

17. Advanced Renal Cell Carcinoma KOL Views

18. Advanced Renal Cell Carcinoma Market Access and Reimbursement

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Renal Cell Carcinoma Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Aplastic Anemia Treatment Market Size in the 7MM was ~USD 270 million in 2023 and is further expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Aplastic Anemia Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Aplastic Anemia, historical and forecasted epidemiology, as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Aplastic Anemia Market Share @ Aplastic Anemia Market Outlook

Key Takeaways from the Aplastic Anemia Market Report

In May 2025, Emory University announced a study will enroll 30 pediatric patients with serious non-malignant hematologic diseases (NMHD) undergoing URD HSCT. The trial will include patients with 7/8 donors and those with 8/8 (matched) donors. All participants will receive 8 doses of abatacept. Recruitment is expected to last for about 2 years and participants will be followed for up to 3 years.
In May 2025, Medical College of Wisconsin conducted a study is a prospective, multicenter Phase II study of hematopoietic stem cell transplantation for previously untreated patients with severe aplastic anemia (SAA). Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. Patients with aplastic anemia have low white blood cells (cells which fight infection), low red blood cells (cells that carry oxygen throughout the body), and low platelets (cells that help form clots and prevent bleeding). Treatments for SAA seeks to repair this abnormal immune system attack and allow the bone marrow to make the normal amount of blood cells. This can be done with a bone marrow transplant or with medications to suppress the immune system.
In May 2025, Fred Hutchinson Cancer Center organized phase II trial tests how well a ruxolitinib-based graft versus host disease (GVHD) prevention (prophylaxis) regimen works before, during, and after bone marrow/stem cell transplantation (hematopoietic cell transplantation [HCT]) in patients with acquired aplastic anemia. Acquired aplastic anemia (AA) is a condition in which the bone marrow is unable to produce blood cells.
The total Aplastic Anemia Treatment Market Size was found to be ~USD 270 million in 2023 in the 7MM, which is further expected to increase by 2034.
Among the 7MM, Japan accounts for the second highest total aplastic anemia drugs market. The Aplastic Anemia Treatment Market Size in Japan has been assessed to be ~USD 35 million in 2023, expected to increase during the forcast period.
During the forecast period, Aplastic Anemia pipeline candidates such as Omidubicel-onlv, REGN7257, and ALVAIZ (eltrombopag choline) are expected to drive the rise in Aplastic anemia market size.
Among EU4 and the UK, Germany accounts for the highest Aplastic Anemia Treatment Market Size with ~USD 14 million in 2023, followed by France.
Aplastic Anemia Treatment Market Size is expected to increase due to several factors such as an increase in disease incidence in Asian countries, high patient uptake of PROMACTA (until expected patent expiry in 2025), approval of Teva Pharma’s ALVAIZ in the US, and Kyowa Kirin’s ROMIPLATE in Japan along with the expected launch of potential emerging therapies.
The leading Aplastic Anemia Companies such as Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals and others.
Promising Aplastic Anemia Pipeline Therapies such as PF-06462700, REGN7257, BL-8040, and Others.

Stay ahead in the Aplastic Anemia Therapeutics Market with DelveInsight’s Strategic Report @ Aplastic Anemia Treatment Market

Aplastic Anemia Epidemiology Segmentation in the 7MM

Aplastic Anemia Incident Cases
Aplastic Anemia Severity-specific Cases
Aplastic Anemia Age-specific Cases

Download the report to understand which factors are driving Aplastic Anemia Epidemiology trends @ Aplastic Anemia Prevalence

Aplastic Anemia Marketed Therapies

ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

ALVAIZ (eltrombopag choline) is an oral thrombopoietin (TPO) receptor agonist that works to increase platelet production by interacting with the transmembrane domain of the human TPO-receptor to initiate signaling cascades that induce proliferation and differentiation of megakaryocytes. Lowest dose of ALVAIZ is use to achieve and maintain a hematologic response. Dose adjustments are based upon the platelet count. Hematologic response requires dose titration, generally up to 108 mg, and may take up to 16 weeks after starting ALVAIZ.

ROMIPLATE (romiplostim; AMG531): Kyowa Kirin/Amgen

ROMIPLATE is composed of recombinant protein acting on the thrombopoietin receptor, which has been licensed from Amgen (K-A) to Kyowa Kirin. It was launched as a drug for idiopathic thrombocytopenic purpura (ITP) in April 2011 and for aplastic anemia in patients who had an inadequate response to conventional therapy in June 2019 in Japan. The drug is composed of recombinant protein stimulating hematopoiesis via acting on the thrombopoietin receptors; Acts directly on megakaryocytic progenitor cells and exerts platelet hematopoietic effects. In addition, this drug promotes the proliferation and differentiation of megakaryocytic progenitor cells by binding to and activating thrombopoietin receptors.

Aplastic Anemia Emerging Therapies

REGN7257: Regeneron Pharmaceuticals

It’s a gc cytokine receptor antibody that targets the common g chain (gc; IL-2RG) found in interleukin (IL) receptors for various gc cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. It was developed to investigate the potential of targeting gc cytokines for the prevention and treatment of T-cell-mediated diseases. By blocking the signaling of GC cytokines, REGN7257 aims to ameliorate T-cell-mediated pathogenesis. This antibody offers a promising approach to understand better the role of gc cytokines in inflammatory and autoimmune disease settings, where the lack of appropriate neutralizing antibodies recognizing IL-2RG has been a challenge.

OMISIRGE (omidubicel): Gamida Cell

OMISIRGE is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. It is indicated for use in adults and pediatric patients aged 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning. The therapy aims to reduce the time to neutrophil recovery and the incidence of infection in this patient population. Omisirge has received approval for use in hematological malignancies and is currently undergoing evaluation in an ongoing investigator-sponsored Phase I/II study focusing on patients with severe aplastic anemia.

To learn more about Aplastic Anemia Treatment guidelines, visit @ Aplastic Anemia Clinical Trials Assessment

Aplastic Anemia Companies

Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals and others.

Aplastic Anemia Market Outlook

The Aplastic Anemia Prognosis, varies based on the severity of the condition. Some cases can be successfully treated, while others may progress to severe complications, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically, the primary modalities for treating aplastic anemia have been IST and BMT in eligible patients. For individuals with SAA/VSAA deemed suitable for transplant-based interventions, age emerges as a pivotal determinant influencing survival post-matched sibling donor (MSD) allogeneic transplantation. Notably, older patients, often having undergone prior IST, presenting with additional comorbidities, diminished performance status, and an extended duration between diagnosis and BMT, exhibit distinctive challenges in outcomes, with fludarabine-containing regimens offering more promising results in this demographic, albeit based on limited retrospective analyses.

Aplastic Anemia Treatment Market

Because newly authorized Aplastic Anemia drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

Learn more about the FDA-approved drugs for Aplastic Anemia @ Drugs for Aplastic Anemia Treatment

Scope of the Aplastic Anemia Market Report

Coverage- 7MM
Study Period- 2020-2034
Aplastic Anemia Companies- Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals and others.
Aplastic Anemia Pipeline Therapies- PF-06462700, REGN7257, BL-8040, and Others.
Aplastic Anemia Market Dynamics: Aplastic Anemia Market Drivers and Barriers
Aplastic Anemia Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Aplastic Anemia

4. Aplastic Anemia Market Overview at a Glance

5 Key Events

6 Epidemiology and Market Forecast Methodology

7 Disease Background and Overview

8 Treatment and Management of Aplastic Anemia

9 Epidemiology and Patient Population

10 Patient Journey

11 Aplastic Anemia Marketed Therapies

12 Aplastic Anemia Emerging Drugs

13 Aplastic Anemia: Market Analysis

14 Aplastic Anemia Unmet Needs

15 Aplastic Anemia SWOT Analysis

16 Aplastic Anemia KOL Views

17 Aplastic Anemia Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aplastic Anemia Treatment Market Size in the 7MM was ~USD 270 million in 2023 and is further expected to increase by 2034, estimates DelveInsight

Biliary Tract Cancer Market Size in the 7MM was ~USD 1000 million in 2023 and is expected to increase a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Biliary Tract Cancer Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Biliary Tract Cancer, historical and forecasted epidemiology, as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Biliary Tract Cancer Market Share @ Biliary Tract Cancer Market Outlook

Key Takeaways from the Biliary Tract Cancer Market Report

In June 2025, AstraZeneca announced a study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator’s choice of chemotherapy in participants with BTC after surgical resection with curative intent.
In June 2025, Merck Sharp & Dohme LLC conducted a Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers.
In the 7MM, the United States accounted for the highest Biliary Tract Cancer market size, with nearly 48% of the market share of the Biliary Tract Cancer market as compared to EU4 and the UK and Japan in 2023.
In 2023, among EU4 and the UK, Italy accounted for the largest Biliary Tract Cancer market size, while Spain accounted for the smallest Biliary Tract Cancer market share.
The clinical features of Biliary Tract Cancer depend on the location of the tumor. Patients with extrahepatic tumors usually present with painless jaundice from biliary obstruction, and patients with intrahepatic tumors usually present with pain. Common complaints include pruritus, abdominal pain, malaise, fatigue, pruritus jaundice, and fever.
Biliary tract cancer is usually diagnosed with the clinical examination of the abdomen, using imaging scans, ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT), and biopsy.
In 2023, Japan accounted for the highest number of total incident cases of Biliary Tract Cancer in the 7MM.
In the United States, Biliary Tract Cancer occurs majorly in the age group of 70–79 years, constituting approximately ~30% of the total age-specific cases of Biliary Tract Cancer.
Among the EU4 and the UK, the mutation-specific cases of Biliary Tract Cancer were highest in TP53 mutations, followed by KRAS mutations in 2023.
The leading Biliary Tract Cancer Companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
Promising Biliary Tract Cancer Pipeline Therapies such as Durvalumab, Nivolumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine, XmAb20717, ZW25 (Zanidatamab) and others.

Stay ahead in the Biliary Tract Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Biliary Tract Cancer Treatment Market

Biliary Tract Cancer Epidemiology Segmentation in the 7MM

Total Biliary Tract Cancer Incident Cases
Biliary Tract Cancer Age-specific Cases
Biliary Tract Cancer Stage-specific Cases
Total Incident Cases of Biliary Tract Cancer by tumor location in the 7MM
Biliary Tract Cancer Mutation-specific Cases
Biliary Tract Cancer Treated Cases

Download the report to understand which factors are driving Biliary Tract Cancer Epidemiology trends @ Biliary Tract Cancer Prevalence

Biliary Tract Cancer Marketed Drugs

PEMAZYRE (pemigatinib): Incyte

PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on the overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMFINZI (durvalumab): AstraZeneca

IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with gemcitabine and cisplatin as treatment of adult patients with locally advanced or metastatic Biliary Tract Cancer.The approval for the treatment of adult patients with locally advanced or metastatic by the US FDA was based on the results from the TOPAZ-1 Phase III trial.

Biliary Tract Cancer Emerging Therapies

CTX-009: Compass Therapeutics

CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of CTX-009 suggest that blockade of both pathways provides robust antitumor activity across several solid tumors, including colorectal cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer, and non-small cell lung cancer. Partial responses to CTX-009 as monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to currently approved anti-VEGF therapies.

Zanidatamab: Jazz Pharmaceuticals/Zymeworks

Zanidatamab is a novel, late-stage oncology asset with the potential to transform the standard of care in multiple HER2-expressing cancers. It has demonstrated compelling data in biliary tract cancers and gastroesophageal adenocarcinoma with the potential to benefit patients across multiple tumor types.A pivotal Phase II clinical trial evaluating zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified Biliary Tract Cancer.

To learn more about Biliary Tract Cancer Treatment guidelines, visit @ Biliary Tract Cancer Clinical Trials Assessment

Biliary Tract Cancer Companies

Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.

Biliary Tract Cancer Market Outlook

Bile duct cancer begins when healthy cells in the bile duct change and grow out of control, forming a mass called a tumor. A tumor can be benign or cancerous. A benign tumor can grow but will not spread. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. Treatment options for the early-stage disease include surgery, followed by adjuvant chemotherapy. For patients with locally advanced and metastatic disease, the combination of gemcitabine and cisplatin has been shown to improve survival.

Biliary Tract Cancer Treatment Market

The biliary tract comprises of gallbladder and intra and extrahepatic biliary tree. Bile is directed through these ducts to the second part of duodenum at major duodenal papilla. The epithelium of the biliary tract is lined with cells called cholangiocytes. Carcinoma of the biliary tract arises from the malignant transformation of the epithelium of the bile ducts which is made up of these cholangiocytes, and is categorized on the basis of its anatomical location as; 1) Intrahepatic cholangiocarcinoma 2) Extrahepatic cholangiocarcinoma, which includes; perihilar tumor also known as Klatskin tumor (originating from the epithelium of the bile duct at the junction of right and left hepatic ducts with the cystic duct where it forms the common bile duct) and distal cholangiocarcinoma outspreading to encompass the gallbladder, ampulla of Vater and pancreatic biliary ducts.

Learn more about the FDA-approved drugs for Biliary Tract Cancer @ Drugs for Biliary Tract Cancer Treatment

Scope of the Biliary Tract Cancer Market Report

Coverage- 7MM
Study Period0- 2020-2034
Biliary Tract Cancer Companies- Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
Biliary Tract Cancer Pipeline Therapies- Durvalumab, Nivolumab, Futibatinib, Ivosidenib, Zanidatamab, Gemcitabine, XmAb20717, ZW25 (Zanidatamab) and others.
Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer Market Drivers and Barriers
Biliary Tract Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Biliary Tract Cancer (BTC)

4. Key Events

5. Biliary Tract Cancer Market Overview at a Glance

6. Disease Background and Overview

7. Current Treatment Practices of Biliary Tract Cancer

8. Guidelines: Diagnosis and Treatment

9. Biliary Tract Cancer Epidemiology and Market Forecast Methodology

10. Biliary Tract Cancer Epidemiology and Patient Population

11. Biliary Tract Cancer Patient Journey

12. Marketed Biliary Tract Cancer Therapies

13. Emerging Biliary Tract Cancer Therapies

14. Biliary Tract Cancer (BTC) Market Analysis

15. Biliary Tract Cancer Unmet Needs

16. Biliary Tract Cancer SWOT Analysis

17. KOL Views

18. Biliary Tract Cancer Market Access and Reimbursement

19. Biliary Tract Cancer Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tract Cancer Market Size in the 7MM was ~USD 1000 million in 2023 and is expected to increase a significant CAGR by 2034, estimates DelveInsight

Vision Marine Secures U.S. Battery Supply Chain Through Strategic Expansion with Octillion Power Systems

U.S.-Assembled 45.36 kWh High-Voltage Packs from Nevada Facility to Promote Accelerated OEM and Consumer Growth Through E-Motion™ Platform

MONTREAL, QC – June 11, 2025 – Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a pioneer in high-voltage electric marine propulsion systems, today announced a major milestone in its U.S. scale-up strategy: the expansion of its longstanding partnership with Octillion Power Systems, a top-tier U.S.-based lithium-ion battery manufacturer, to produce Vision-branded high-voltage battery packs dedicated exclusively to the American market.

Under the terms of the agreement, Octillion will assemble Vision Marine’s new proprietary 45.36 kWh battery packs at its state-of-the-art facility in Nevada, aiding in fast, cost-efficient distribution across North America. These batteries are designed to support both Vision Marine’s OEM integrations and consumer-facing electric boat offerings, delivering increased power, extended range, and improved performance-while reducing total system cost and simplifying logistics.

This renewed and enhanced partnership establishes a partial U.S. supply chain for Vision Marine’s proprietary E-Motion™ 180E electric outboard system, unlocking key efficiencies. In addition to supporting factory integration with third-party manufacturers, the partnership provides a reliable and consistent battery supply for Vision Marine’s direct-to-consumer electric boat sales, including those produced under formal production agreements with multiple established boat manufacturers. These vessels are sold through Vision Marine’s channels while retaining the original manufacturer’s branding, enabling broad market reach without altering brand identity.

“Octillion has been an integral technology partner to Vision Marine for several years, powering our most high-performance programs-including multiple electric world speed record boats,” said Alexandre Mongeon, CEO of Vision Marine Technologies. “With this expanded partnership and the support of Octillion’s Nevada facility, we are positioned to scale commercial deliveries and prepare for our next record-setting performance with more power and higher efficiency.”

Founded in 2009 and headquartered in California, Octillion Power Systems is a global leader in lithium-ion battery technology, with over 2 million battery systems deployed across electric vehicles, industrial equipment, and energy storage sectors. Octillion brings deep technical expertise and proven large-scale manufacturing capabilities-essential components to Vision Marine’s growth roadmap.

“Having collaborated with Vision Marine since 2021 on the development of this American-built, marine-dedicated battery platform has been both technically rewarding and strategically significant,” said Paul Beach, President of Octillion Power Systems. “We are proud to manufacture these 45.36 kWh packs at our Nevada facility and to work in close alignment with Vision Marine’s team as they scale delivery and continue to push the boundaries of electric propulsion on water.”

In addition to supporting near-term production, Octillion’s close proximity and embedded technical collaboration introduce a new phase in Vision Marine’s development strategy. By aligning with a team that has delivered over 2 million battery systems globally, Vision Marine is now embracing a more agile, partner-integrated model of innovation, leveraging Octillion’s energy systems expertise to guide refinements and influence the evolution of future battery architectures.

The battery systems being manufactured by Octillion are integrated with Vision Marine’s patent-pending proprietary high-voltage marine propulsion powertrain -the first battery pack purpose-built for electric marine propulsion. Engineered to meet the demanding conditions of marine use, these packs deliver enhanced energy density, ruggedness, and integration simplicity-promoting optimal performance across a wide range of recreational and commercial applications.

The packs will be available exclusively with the E-Motion™ 180E outboard and offered as part of a fully integrated, plug-and-play powertrain solution. Designed for rapid OEM adoption and simplified factory installation, this system addresses long-standing industry barriers to electric adoption-namely cost, complexity, and limited performance.

By leveraging Octillion’s Nevada-based production infrastructure and forward-leaning technical engagement, Vision Marine becomes the first company in North America offering a fully industrialized, high-voltage electric marine outboard system with a U.S.-sourced battery solution -positioning the Company to meet growing demand for electrified boating while supporting regulatory and content compliance initiatives.

With domestic battery sourcing secured, enhanced pack performance, and ongoing collaboration with Octillion’s technical team, Vision Marine enters the second half of 2025 with the foundation to scale its go-to-market operations and accelerate its innovation agenda. As the Company advances, it remains committed to shaping the future of marine electrification by embracing cross-functional partnerships and leading-edge development models to bring next-generation technologies to the water.

About Octillion Power Systems

Octillion Power Systems is a U.S.-based global provider of advanced lithium-ion battery solutions for electric mobility and stationary energy storage. With over 2 million battery packs shipped worldwide, Octillion specializes in scalable, safe, and high-performance battery packs for transportation, industrial, and grid-connected applications. Visit www.octillion.us to learn more.

About Vision Marine Technologies Inc.

Vision Marine Technologies Inc. (NASDAQ:VMAR) is a pioneer in marine electrification. Its flagship E-Motion™ 180E system is a fully integrated high-voltage electric outboard powertrain built for OEM adoption at scale. Vision Marine designs and manufactures electric propulsion systems and boats to transform recreational and commercial boating into a zero-emission experience. Learn more at www.visionmarinetechnologies.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These statements include, but are not limited to, expectations regarding the benefits of the new patent, its impact on future product development and original equipment manufacturer integrations, and Vision Marine’s competitive position. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect results are discussed in the Company’s filings with the Securities and Exchange Commission. Vision Marine undertakes no obligation to update any forward-looking statements except as required by law.

Investor & Company Contact

Vision Marine Technologies

Bruce Nurse – Investor Relations

(303) 919-2913

bn@v-mti.com

Website: visionmarinetechnologies.com

Twitter: @marine_vision

Facebook: @VisionMarineTechnologies

Instagram: @visionmarine.technologies

YouTube: @VisionMarineTechnologies

Media Contact
Company Name: Microcap Headlines, Inc.
Contact Person: Natalie Peccia
Email: Send Email
Phone: (888) 254-2227
Country: United States
Website: http://www.microcapheadlines.com/

From Breakdown to Breakthrough: Mabel Pantaleon Releases Poetic Memoir About Thriving With Bipolar Disorder

NEW YORK, NY – June 11th, 2025 – Author, speaker, and mental health advocate Mabel Pantaleon announces the release of her powerful and poetic memoir, My Diagnosis is My Greatest Gift and My Greatest Teacher: A Personal Guide to Thrive With Bipolar Disorder — a transformative narrative that reimagines bipolar disorder not as a life sentence, but as a spiritual teacher and hidden gift.

Pantaleon’s memoir offers an unfiltered look at what it means to live with bipolar disorder — from the terrifying beauty of manic episodes to the quiet courage it takes to heal. Her story blends lived experience with spiritual insight, providing a beacon of hope for those navigating mental illness, stigma, or personal transformation.

“I didn’t just survive bipolar — I grew because of it,” says Pantaleon. “This diagnosis cracked me open, and in that opening, I discovered truth, purpose, and the strength to rebuild.”

Drawing from metaphysical teachings, psychiatric treatment, and personal growth, the book includes:

Vivid depictions of manic and depressive episodes
Reflections on spiritual awakening and mystical experiences
Guidance for those balancing psychiatric medication with faith or metaphysical beliefs
Practical tools and emotional support for those seeking to thrive — not just cope

In tandem with her book, Mabel also founded the nonprofit Echoes of the Divine, a support initiative for individuals on psychiatric medications seeking holistic healing, spiritual community, and self-empowerment.

To learn more about Echoes of The Divine, access resources, or get involved, visit:

www.MabelPantaleon.com

www.EchoesOfTheDivine.org

MabelPantaleon@gmail.com

Instagram: @therealmabelpantaleon

LinkedIn: Mabel Pantaleon

About the Author:

Mabel Pantaleon is a Dominican-American writer, mental health advocate, and founder of Echoes of the Divine, a nonprofit dedicated to supporting individuals navigating psychiatric treatment through a spiritual lens. Based in New York City, her work blends lived experience with metaphysical teachings to inspire healing, empowerment, and awakening.

Media Contact
Company Name: Mabel Pantaleon
Contact Person: Mabel Pantaleon
Email: Send Email
Country: United States
Website: www.MabelPantaleon.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: From Breakdown to Breakthrough: Mabel Pantaleon Releases Poetic Memoir About Thriving With Bipolar Disorder

AllColorScreen.com Grows From a Basic Display-Testing Page to a Robust Web Toolkit

When Eugene Ivanov first launched AllColorScreen.com, he had one modest aim: to create a single-page, no-frills resource for testing computer monitors. Today, that simple idea has blossomed into an online collection of more than forty browser-based utilities—ranging from essential display diagnostics to playful interactive gadgets.

A Modest Beginning

Eugene recalls the moment his own monitor began showing uneven backlight: “I searched for a quick way to check my screen, but every tool I found felt overbuilt. I thought, ‘Why not make something that just works, instantly, in any browser?’” Within days, he had coded basic solid-color screens and a dead-pixel checker, all accessible with a single click.

Building on a Simple Foundation

The site’s capabilities were expanded in response to feedback from early users. Over successive weekends, he added uniformity and sharpness tests, a response-time analyzer and gamma-calibration checker. Next came color-contrast and pixel-density calculators, followed by aspect-ratio and projector-screen tools—each designed for clarity and ease of use.

A Blend of Utility and Whimsy

More recently, AllColorScreen.com has welcomed a suite of interactive features: a Random Color Generator for designers, a Gradient Maker, and a Color Distance Test to fine-tune palettes. For those in search of a moment’s diversion, the site offers a Bouncing DVD Logo screensaver, a Fake Broken Screen prank, a White Noise Generator and even a Hacker Typer simulator.

Every tool on AllColorScreen.com requires no download or registration. The clean, mobile-friendly interface delivers instant results on desktops, tablets and smartphones alike. Users may save their findings or share links, making the site a handy companion for IT technicians, photographers, gamers—and anyone who uses a screen.

Looking Forward

With its roots in uncomplicated display testing, AllColorScreen.com plans to roll out new diagnostics and utilities throughout 2025. As Mr. Ivanov puts it, “Whether you need precise color calibration or just a quick laugh, our goal is to keep it fast, free and reliable.”

Availability

AllColorScreen.com is live and free to use worldwide. Visit https://allcolorscreen.com to explore the full range of tools.

Media Contact
Company Name: IVKO Solutions LLC
Contact Person: Eugene Ivanov
Email: Send Email
Country: United States
Website: https://allcolorscreen.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AllColorScreen.com Grows From a Basic Display-Testing Page to a Robust Web Toolkit

Giant-Cell Arteritis Market Set for Transformative Growth with Novel Therapies and Aging Demographics Driving Demand | DelveInsight

“Giant-Cell Arteritis Market Insights- DelveInsight”

The giant-cell arteritis market is poised for notable growth across the 7MM, driven by an aging population and the anticipated launch of innovative therapies by companies such as Novartis, AbbVie, and J&J/MorphoSys AG, among others.

DelveInsight’s “Giant-Cell Arteritis Market Insight, Epidemiology and Market Forecast – 2034” report offers comprehensive insights into giant-cell arteritis epidemiology, current and emerging therapies, market trends, and giant-cell arteritis forecasts.

The giant-cell arteritis market is expected to grow from USD 960 million in 2023, driven by the rising geriatric population, increasing prevalence of cardiovascular disorders, and ongoing clinical advancements by several pharmaceutical companies.

Download the Giant-Cell Arteritis Market report to understand which factors are driving the Giant-Cell Arteritis therapeutic market @ Giant-Cell Arteritis Market Trends.

Giant-cell arteritis, also known as temporal arteritis, is a large-vessel vasculitis that primarily affects the arteries of the head, especially the temporal arteries. The disease is characterized by inflammation that can lead to narrowing and reduced blood flow, with potential consequences such as vision loss and stroke. Its etiology is complex, involving genetic factors as well as environmental triggers. The pathogenesis involves a dual immune response, with IL-6 playing a central role in mediating systemic inflammation.

DelveInsight’s analysis of giant-cell arteritis epidemiology reveals that the US accounted for the highest number of diagnosed giant-cell arteritis prevalent cases in 2023, representing 54% of all diagnosed prevalent cases across the 7MM. The burden of giant-cell arteritis is particularly pronounced among the elderly, with individuals aged 80–89 years constituting approximately 42% of total cases in the US. This underscores the strong association between giant-cell arteritis and the aging population.

Among the European countries, the UK held the highest number of giant-cell arteritis cases, followed by France, while Spain accounted for the lowest number of cases. In Japan, as in Europe, scalp tenderness was the most frequent clinical manifestation, followed by myalgia and fever of unknown origin, highlighting the heterogeneity of clinical presentations across different regions.

Discover evolving trends in the Giant-Cell Arteritis patient pool forecasts @ Giant-Cell Arteritis Epidemiology Analysis.

Giant-cell arteritis diagnosis remains challenging due to the heterogeneity of its clinical presentation. The American College of Rheumatology’s criteria form the diagnostic cornerstone. However, no single test is definitive. Physicians rely on a combination of clinical evaluation, blood tests (ESR, C-reactive protein), imaging modalities such as specialized ultrasound, and the gold-standard temporal artery biopsy to confirm diagnosis and assess vascular involvement.

The current treatment paradigm for giant-cell arteritis is centered on high-dose corticosteroids (Glucocorticoids), particularly prednisone, administered at 40–60 mg daily for three to four weeks, followed by gradual tapering. Immediate initiation of therapy is critical to prevent irreversible complications such as blindness. Despite their efficacy, long-term corticosteroid use is associated with significant adverse effects, including osteoporosis, diabetes, and hypertension, highlighting the need for alternative therapies. Conventional disease-modifying anti-rheumatic drugs (DMARDs), such as azathioprine and mycophenolate mofetil, are sometimes used adjunctively but with limited success.

The therapeutic landscape has evolved with the introduction of Chugai Pharmaceuticals/Roche’s ACTEMRA/ROACTEMRA (tocilizumab), the only approved therapy for the treatment of giant-cell arteritis in 7MM. Tocilizumab is a first-in-class anti-IL-6 receptor monoclonal antibody that showed a significant increase in sustained remission rates when combined with a steroid taper.

In January 2025, Celltrion’s AVTOZMA, a biosimilar to ACTEMRA, received FDA approval for both intravenous and subcutaneous use, expanding access to advanced therapies for giant-cell arteritis and other autoimmune diseases. Furthermore, in April 2025, the FDA and EMA approved AbbVie’s RINVOQ (Upadacitinib) for Giant Cell Arteritis treatment, providing an alternative treatment option that can offer patients with GCA the possibility of tapering off steroids and achieving sustained remission. Upadacitinib is projected to capture the largest market share in the 7MM by 2034.

Several promising therapies are in late-stage clinical development and are expected to reshape the giant-cell arteritis management over the next decade. Novartis’ COSENTYX (secukinumab), a monoclonal antibody targeting interleukin-17A (IL-17A), and Johnson & Johnson/MorphoSys AG’s TREMFYA (guselkumab), an IL-23p19 inhibitor, are advancing through clinical development. CSL/Kiniksa’s mavrilimumab, a granulocyte-macrophage colony-stimulating factor receptor antagonist, further reflects the diversification of therapeutic targets in giant-cell arteritis.

Discover recent advancements in the Giant-Cell Arteritis treatment landscape @ Giant-Cell Arteritis Recent Developments.

Looking ahead, the giant-cell arteritis market is expected to benefit from continued innovation and an aging population. As companies advance novel therapeutics and address longstanding unmet needs, the market is set for transformation, offering improved outcomes for patients at risk of this autoimmune complication. However, challenges such as delays in diagnosis, risk of serious complications, economic burden, and gaps in disease understanding continue to impact the market’s trajectory. For industry participants and healthcare providers, staying abreast of these developments is essential for optimizing treatment strategies and capitalizing on emerging opportunities in the giant-cell arteritis market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Giant-Cell Arteritis

4. Giant-Cell Arteritis Market Overview at a Glance

5. Disease Background and Overview

6. Diagnosis of Giant-Cell Arteritis

7. Diagnostic Guidelines

8. Treatment of Giant-Cell Arteritis

9. Treatment Guidelines

10. Epidemiology and Market Forecast Methodology

11. Giant-Cell Arteritis Epidemiology and Patient Population

12. Giant-Cell Arteritis Patient Journey

13. Giant-Cell Arteritis Marketed Therapies

14. Giant-Cell Arteritis Emerging Therapies

15. Giant-Cell Arteritis: Market Analysis

16. Giant-Cell Arteritis Unmet Needs

17. SWOT Analysis

18. KOL Views

19. Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:

Giant-Cell Arteritis Pipeline Insight

Giant-Cell Arteritis Pipeline Insight provides comprehensive insights about the Giant-Cell Arteritis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Giant-Cell Arteritis companies, including Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, and Dr Reddy’s Laboratories, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Giant-Cell Arteritis Market Set for Transformative Growth with Novel Therapies and Aging Demographics Driving Demand | DelveInsight

Vitiligo Treatment Market Set for Robust Growth Through 2034, Driven by Recent Developments in Clinical Development Pipeline | DelveInsight

The vitiligo treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key players, including Incyte, Pfizer, AbbVie, Astellas, Dr. Reddy’s, Bausch Health, MSD, BMS, Novartis, Arcutis, Dermavant, Aclaris, Glenmark, Clinuvel, Edesa Biotech, STRATA Skin Sciences, Temprian, Villaris, Boston Pharmaceuticals, Applied Biology, Panacea Biotech, Viatris, Teva, Salix, and Vyne Therapeutics, among others.

DelveInsight’s “Vitiligo Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the vitiligo treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and vitiligo market forecasts through 2034, providing crucial insights for stakeholders in the vitiligo therapeutic area.

According to DelveInsight’s analysis, the vitiligo treatment market is projected to grow substantially with a decent CAGR during the forecast period, driven by enhanced understanding of disease mechanisms, biomarker development, and personalized medicine approaches.

Download the Vitiligo Market report to understand which factors are driving the Vitiligo therapeutic market @ Vitiligo Market Trends.

According to DelveInsight’s estimates, the 12-month prevalence of vitiligo was 8.2 million in 2023 across the 7MM, with nearly 500K cases treated. Both prevalence and treatment rates are projected to increase over the forecast period (2025–2034). Furthermore, the US accounted for approximately 60% of the total diagnosed vitiligo cases in the 7MM. Within EU4 and the UK, Germany reported the highest vitiligo patient share, followed by the UK, while Spain had the lowest.

The DelveInsight report further categorizes the vitiligo patient population into several main groups for analysis. It differentiates between segmental vitiligo and non-segmental vitiligo. Non-segmental vitiligo is more common, typically symmetrical, and can be classified into several subtypes, including acrofacial, mucosal, generalized, universal, mixed, and rare forms. Mixed vitiligo refers to instances where both segmental and non-segmental patterns are observed in the same patient. Additionally, there are unclassified forms, such as focal vitiligo (characterized by isolated patches) and cases that do not fit neatly into the other categories. This classification is essential for understanding the distribution, progression, and treatment responses of different vitiligo types and is crucial for accurate epidemiological assessment.

Discover evolving trends in the Vitiligo patient pool forecasts @ Vitiligo Epidemiology Analysis.

While there is no definitive cure for vitiligo, several treatment options are aimed at vitiligo management and potentially reversing depigmentation. A milestone in vitiligo treatment occurred with the FDA approval of OPZELURA (ruxolitinib cream) by Incyte in July 2022, marking the first pharmacologic therapy specifically approved for repigmenting nonsegmental vitiligo. This topical JAK inhibitor has revolutionized the treatment landscape by targeting the underlying inflammatory pathways that drive melanocyte destruction. OPZELURA continues to demonstrate strong market uptake, addressing a critical unmet need in this challenging autoimmune skin disorder.

According to the DelveInsight report, the vitiligo therapies pipeline is robust and promising, with several novel treatments in late-stage development. AbbVie’s RINVOQ (upadacitinib), a selective JAK1 inhibitor currently in Phase III clinical trials, has shown encouraging results with clinically meaningful repigmentation of extensive vitiligo after 52 weeks of treatment. Similarly, Pfizer’s LITFULO (ritlecitinib), targeting JAK3 and TEC kinase family pathways, has demonstrated efficacy in early trials and is progressing through Phase III development with potential approval anticipated in the coming years.

Recent developments highlight the dynamic nature of the vitiligo treatment landscape. In January 2025, VYNE Therapeutics completed patient enrollment in its Phase IIb trial assessing VYN201 gel (repibresib) for nonsegmental vitiligo, with top-line data expected in mid-2025. This novel pan-bromo domain and extra-terminal domain (BET) inhibitor has shown promising results in earlier trials, demonstrating significant clinical response with rapid onset of action and favorable safety profile. Additionally, Incyte’s povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, has reported positive data from its Phase IIb trial in extensive nonsegmental vitiligo patients, further expanding the treatment options on the horizon.

Furthermore, in March 2025, a pre-clinical study revealed that a natural compound derived from gut-friendly bacteria can significantly slow the progression of vitiligo in mice and may help restore skin pigmentation.

Discover recent advancements in the Vitiligo treatment landscape @ Vitiligo Recent Developments.

The vitiligo treatment market is highly competitive, with major players including Incyte (NASDAQ: INCY), Pfizer (NYSE: PFE), AbbVie (NYSE: ABBV), Astellas (TSE: 4503), Dr. Reddy’s (NYSE: RDY), Bausch Health (NYSE: BHC), Merck– (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS) Arcutis(NASDAQ: ARQT), Dermavant, Aclaris (NASDAQ: ACRS), Glenmark (NSE: GLENMARK), Clinuve (ASX: CUV)l, Edesa Biotech (NASDAQ: EDSA), STRATA Skin Sciences (NASDAQ: SSKN), Temprian, Villaris, Boston Pharmaceuticals, Applied Biology, Panacea Biotech (BSE: 531349), Viatris (NASDAQ: VTRS), Teva (NYSE: TEVA), Salix, and Vyne Therapeutics (NASDAQ: VYNE), all advancing a variety of therapies through robust R&D and strategic collaborations.

Looking ahead, the vitiligo market is expected to witness continued innovation driven by enhanced understanding of disease mechanisms, biomarker development, and personalized medicine approaches. While significant progress has been made with JAK inhibitors, challenges remain in addressing complete repigmentation, preventing disease recurrence, and improving treatment accessibility and affordability across diverse patient populations. Emerging therapies focusing on novel mechanisms beyond JAK inhibition, including targeted immunomodulators and melanocyte-stimulating agents, hold promise for addressing these unmet needs and further transforming the vitiligo treatment landscape.

DelveInsight’s analysis underscores that despite therapeutic advances, substantial opportunities remain for developing more effective, convenient, and affordable treatment options that can achieve durable repigmentation and improved quality of life for vitiligo patients worldwide. As research continues and awareness grows, the vitiligo market is poised for remarkable expansion and therapeutic innovation through 2034.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Vitiligo

4. Key Events

5. Vitiligo Epidemiology and Market Forecast Methodology

6. Vitiligo Market Overview at a Glance

7. Vitiligo Background and Overview: Vitiligo

8. Vitiligo Treatment and Management

9. Vitiligo Epidemiology and Patient Population of Vitiligo in the 7MM

10. Vitiligo Patient Journey

11. Vitiligo Marketed Therapies

12. Vitiligo Emerging Therapies

13. Vitiligo: Seven Major Market Analysis

14. Vitiligo Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Vitiligo Pipeline Insight

Vitiligo Pipeline Insight provides comprehensive insights about the Vitiligo pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Vitiligo companies, including AbbVie, Pfizer, Incyte Corporation, Dren Bio, and Amgen, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vitiligo Treatment Market Set for Robust Growth Through 2034, Driven by Recent Developments in Clinical Development Pipeline | DelveInsight

Febrile Neutropenia Treatment Market Expected to Grow Notably, Driven by Introduction of Innovative Therapies | DelveInsight

“Febrile Neutropenia Market Insights – DelveInsight”

The Febrile Neutropenia market is poised for notable growth across the 7MM, driven by the increasing incidence of febrile neutropenia among cancer patients undergoing chemotherapy and the anticipated launch of innovative therapies by companies such as Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, and Bristol-Myers Squibb, among others.

DelveInsight’s report titled “Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast – 2032“, combines comprehensive febrile neutropenia epidemiological data with market trends, an examination of the competitive landscape, and assessments of the patient journey. This report provides valuable insights into the rapidly growing febrile neutropenia market. It is anticipated that the market will expand significantly during the forecast period from 2023 to 2032, driven by an increasing patient population and the introduction of innovative treatment options by leading pharmaceutical and biotechnology companies, including Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, among others.

Furthermore, the US currently represents the largest market, with the EU4, the UK, and Japan contributing significantly to the overall patient population and market opportunity.

Download the Febrile Neutropenia Market report to understand which factors are driving the Febrile Neutropenia therapeutic market @ Febrile Neutropenia Market Trends.

Febrile neutropenia is a critical and potentially life-threatening complication, most commonly arising as a severe side effect of cancer therapies such as chemotherapy and radiation. Characterized by fever and a markedly reduced neutrophil count, this condition leaves patients highly vulnerable to infections that can escalate rapidly.

Epidemiologically, the febrile neutropenia burden is substantial and growing. DelveInsight’s analysis provides a comprehensive overview of febrile neutropenia patient pools across the 7MM, with segmentation by country and key demographic factors. Notably, approximately 50% of patients with febrile neutropenia develop an infection, and up to 20% of those with severe neutropenia may develop bacteremia. The risk is higher in patients with blood cancers and in those on strong chemotherapy regimens. Older age, poor overall health, and other medical conditions can also increase the risk.

Discover evolving trends in the Febrile Neutropenia patient pool forecasts @ Febrile Neutropenia Epidemiology Analysis.

Febrile neutropenia management strategies currently involve rapid initiation of broad-spectrum antibiotics, supportive care measures like hydration and fever control, and, in severe cases, the administration of granulocyte colony-stimulating factors (G-CSF) to stimulate neutrophil production. Despite these established approaches, the market continues to face unmet needs, including the demand for more effective therapies that can reduce infection-related morbidity and mortality, minimize treatment interruptions, and improve overall patient outcomes.

Leading therapies include NEULASTA (pegfilgrastim) and NEUPOGEN (filgrastim), both developed and marketed by Amgen. Neulasta is a long-acting option given as a single injection per chemotherapy cycle, while Neupogen is a daily injectable. The introduction of biosimilars and innovative delivery devices, such as the Neulasta Onpro on-body injector, has helped make these treatments more accessible and convenient for patients, supporting faster recovery and reducing complications from febrile neutropenia

Several promising therapies are currently in the febrile neutropenia therapeutic pipeline, focusing on novel mechanisms and improved patient outcomes. Notably, BeyondSpring Pharmaceuticals is developing plinabulin, which has shown positive results in the DUBLIN-3 Phase 3 trial for chemotherapy-induced neutropenia. In this study, plinabulin combined with docetaxel demonstrated a statistically significant improvement in overall survival for patients with non-small cell lung cancer compared with docetaxel alone. Other companies active in this space include Tianjin SinoBiotech Ltd., Evive Biotech, and Enzychem Lifesciences, each working on innovative candidates at various stages of clinical development. These emerging therapies represent new approaches beyond traditional G-CSF agents, with the potential to further reduce infection risk and improve quality of life for patients undergoing chemotherapy.

Recently, there have been important developments in febrile neutropenia treatment. Notably, new clinical research published in March 2025 evaluated the safety and effectiveness of early antibiotic de-escalation in patients with febrile neutropenia, offering new insights for antimicrobial stewardship and patient care. Additionally, the ASCO 2025 conference featured updated clinical data on efbemalenograstim alfa (RYZNEUTA) for the prevention of febrile neutropenia in patients receiving intermediate-risk chemotherapy regimens, highlighting ongoing advancements in supportive care for cancer patients.

Discover recent advancements in the Febrile Neutropenia treatment landscape @ Febrile Neutropenia Recent Developments.

Looking ahead, the febrile neutropenia market is expected to benefit from continued innovation, a growing patient pool, and heightened awareness of the condition’s clinical impact. As companies advance novel therapeutics and address longstanding unmet needs, the market is set for transformation, offering improved outcomes for patients at risk of this serious complication. For industry participants and healthcare providers, staying abreast of these developments is essential for optimizing treatment strategies and capitalizing on emerging opportunities in the febrile neutropenia market.

Table of Contents

1. Key Insights

2. Executive Summary of Febrile Neutropenia

3. Competitive Intelligence Analysis for Febrile Neutropenia

4. Febrile Neutropenia: Market Overview at a Glance

5. Febrile Neutropenia: Disease Background and Overview

6. Patient Journey

7. Febrile Neutropenia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Febrile Neutropenia Unmet Needs

10. Key Endpoints of Febrile Neutropenia Treatment

11. Febrile Neutropenia Marketed Products

12. Febrile Neutropenia Emerging Therapies

13. Febrile Neutropenia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Febrile Neutropenia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:

Febrile Neutropenia Pipeline Insight

Febrile Neutropenia Pipeline Insight provides comprehensive insights about the Febrile Neutropenia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Febrile Neutropenia companies, including Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, and Bristol-Myers Squibb, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Febrile Neutropenia Treatment Market Expected to Grow Notably, Driven by Introduction of Innovative Therapies | DelveInsight

Smart Warehousing Market to Witness Notable Growth Analysis, Opportunities, and Future Scope Forecast 2030

“Manhattan Associates (US), Körber (Germany), Oracle (US), SAP (Germany), Tecsys (Canada), PSI Logistics (Germany), Samsung SDS (South Korea), Reply (Italy), Magazino (Germany).”

Smart Warehousing Market by Offering (AGVs, AMRs, AS/RS, AIDC, Palletizing & Depalletizing Systems, Conveyors & Sorters, TMS, WMS, Order Management), Technology (AI, IoT, Blockchain, Big Data & Analytics, Robotics & Automation) – Global Forecast to 2030.

The global smart warehousing market is expected to grow at a compound annual growth rate (CAGR) of 8.3% between 2025 and 2030, from an estimated USD 31.21 billion in 2025 to USD 46.42 billion by 2030. Rising e-commerce demand, the requirement for real-time inventory management, and the growing use of cutting-edge technologies like IoT, AI, robots, and cloud computing are all factors propelling the smart warehousing market’s expansion. Predictive maintenance, data-driven decision-making, and a decrease in human error are all made possible by these technologies. Modernization of logistics infrastructure is also being driven by the increasing expectations of consumers for delivery that are more precise and timely. Government programs that encourage the digital transformation of logistics also help the global market grow.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=199732421

Services segment by offering is poised for the fastest growth during the forecast period

The services segment in the smart warehousing market is expected to grow fast during the forecast period due to increasing demand for system integration, maintenance, and support services. As companies adopt IoT, AI, and robotics, expert services are needed to implement and manage these systems effectively. Additionally, the shift to cloud-based solutions drives demand for ongoing technical support. Customization and scalability offered through services also appeal to businesses seeking agile operations. This makes services essential for optimizing smart warehouse performance.

Robotics & Automation Technology will register the largest market share during the forecast period

The robotics and automation technology segment is expected to register the largest market share in the smart warehousing market due to its ability to significantly improve operational efficiency, reduce labor costs, and enhance accuracy in inventory management. As e-commerce and omnichannel retailing grow, the demand for faster order fulfillment and real-time inventory tracking increases, driving the adoption of automated systems such as autonomous mobile robots and robotic picking solutions. These technologies streamline repetitive tasks, minimize human error, and enable 24/7 operations, making them indispensable for modern warehouses.

North America is projected to hold the largest market share during the forecast period

North America is projected to dominate the smart warehousing market due to its early adoption of IoT, AI, and robotics. The region has a strong presence of key market players and a well-established logistics infrastructure. High e-commerce penetration drives demand for efficient and automated warehousing solutions. Additionally, significant investments in digital transformation and supply chain optimization support market growth. Government initiatives and favorable policies also contribute to technological advancements in the sector.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=199732421

Unique Features in the Smart Warehousing Market

Smart warehousing leverages Internet of Things (IoT) devices and sensor-based systems to track inventory in real-time, monitor environmental conditions, and streamline logistics. These technologies enable warehouse managers to make data-driven decisions, reduce manual errors, and ensure better inventory visibility and accuracy.

The market is witnessing a surge in the use of AGVs, drones, and robotic arms for material handling, picking, and sorting. These systems enhance operational efficiency by reducing reliance on human labor, optimizing workflows, and improving speed and safety in warehouse operations.

AI-driven analytics play a critical role in demand forecasting, warehouse optimization, and inventory management. Predictive models help businesses anticipate stock shortages, manage seasonal fluctuations, and plan replenishments, leading to minimized downtime and increased cost savings.

Cloud-enabled WMS platforms offer scalability, real-time data access, and remote monitoring. These systems allow seamless integration with ERP and supply chain platforms, supporting centralized management across multiple warehouse locations and enabling agility in operations.

Major Highlights of the Smart Warehousing Market

The smart warehousing market is experiencing rapid growth driven by rising e-commerce demand, global supply chain disruptions, and the need for operational efficiency. Enterprises are increasingly investing in automation and digitalization to remain competitive and meet consumer expectations for faster deliveries.

While traditionally used in logistics and retail, smart warehousing is now expanding into sectors like manufacturing, healthcare, food & beverage, and automotive. This cross-industry adoption is fueled by the need for improved inventory control, compliance, and streamlined distribution.

Rather than fully replacing human labor, smart warehousing technologies are being used to augment workforce capabilities. Automation handles repetitive tasks, while human workers focus on complex decision-making and value-added services, improving overall productivity and job satisfaction.

AI and machine learning are becoming mainstream in warehouse operations, from robotic automation to intelligent demand planning. The increasing availability of AI-as-a-Service (AIaaS) and advanced analytics tools makes it easier for organizations to adopt smart technologies without heavy infrastructure investments.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=199732421

Top Companies in the Smart Warehousing Market

Some of the leading players in the smart warehousing market include Dematic (US), SSI Schaefer (Germany), Daifuku (Japan), Körber (Germany), and Blue Yonder (US). These players focus on strategic partnerships, continuous innovation, and AI, robotics, and IoT integration to enhance automation and efficiency. They invest in scalable cloud-based platforms, offer end-to-end solutions, and prioritize customer-centric approaches to meet evolving supply chain demands and gain competitive advantage.

Dematic

Dematic is a prominent player in the smart warehousing market, offering a comprehensive range of automation solutions to optimize supply chain operations. The company provides integrated systems that include automated storage and retrieval systems (AS/RS), automated guided vehicles (AGVs), and warehouse control systems (WCS) designed to enhance efficiency and reduce operational costs. Dematic’s solutions particularly benefit e-commerce, retail, and manufacturing industries, where rapid order fulfillment and inventory accuracy are critical. By leveraging advanced technologies, Dematic helps businesses streamline their warehousing processes, improve scalability, and maintain competitiveness in the evolving logistics landscape.

Körber

Körber is one of the prominent players in the smart warehousing market, leveraging its core competencies in warehouse management systems (WMS), automation, robotics, and AI-driven supply chain solutions. The company emphasizes ecosystem development and end-to-end integration, aligning with global megatrends and technology advancements. Körber has strategically expanded through notable acquisitions, including MercuryGate, which has improved its transportation management capabilities, and the mail and parcel business from Siemens Logistics, which has strengthened its automation and software offerings. Additionally, a joint venture with KKR further supports Körber’s growth and innovation initiatives. Through vertical integration and strategic partnerships, Körber delivers comprehensive, scalable solutions across diverse industries, solidifying its position in the global smart warehousing landscape.

SSI Schaefer

SSI Schaefer, based in Germany, is a global leader in smart warehousing solutions, offering integrated systems that combine automation, robotics, and intelligent software to optimize intralogistics operations. Their WAMAS® software suite, encompassing Warehouse Management System (WMS) and Warehouse Control System (WCS), orchestrates complex warehouse processes, ensuring real-time inventory tracking and efficient material flow . Innovations like the Order Verifier and advanced piece-picking robots with integrated image processing enhance accuracy in order fulfillment, particularly in sectors like healthcare and cosmetics where precision is critical . SSI Schaefer’s modular and scalable solutions support businesses of all sizes, facilitating the transition from manual to automated warehousing while ensuring compliance with stringent industry regulations.

Daifuku

Daifuku Co., Ltd., founded in 1937 and headquartered in Osaka, Japan, is a global leader in smart warehousing and intralogistics solutions. Renowned as the world’s top supplier of automated material handling systems, Daifuku offers a comprehensive range of technologies, including Automated Storage and Retrieval Systems (AS/RS), conveyors, sorters, Automated Guided Vehicles (AGVs), and Autonomous Mobile Robots (AMRs). These solutions are tailored for diverse industries such as automotive, e-commerce, pharmaceuticals, and food and beverage, enhancing operational efficiency and adaptability. With a presence in over 25 countries and a significant footprint in India through Daifuku Intralogistics India Private Limited, the company combines Japanese engineering excellence with localized manufacturing to deliver scalable, high-performance warehousing systems. Daifuku’s commitment to innovation is exemplified by its Hini Arata Kan Innovation Center in Japan, showcasing over 400 products and integrated systems, reflecting its dedication to advancing smart warehousing technologies

Blue Yonder

Blue Yonder, based in the United States, is a prominent provider of smart warehousing solutions, offering a comprehensive suite of AI-driven tools designed to optimize end-to-end warehouse operations. Its Warehouse Management System (WMS) integrates seamlessly with labor management, yard operations, and robotics orchestration, enabling real-time visibility and intelligent task prioritization across distribution centers and micro-fulfillment hubs. Recognized as a Leader in the 2024 Gartner Magic Quadrant for Warehouse Management Systems for the 13th consecutive year, Blue Yonder serves clients across 19 industries, including retail, logistics, automotive, and life sciences. The company’s cloud-native platform supports advanced features such as dynamic task sequencing, resource capacity smoothing, and automated escalation protocols, helping businesses enhance throughput, reduce costs, and improve service levels. Blue Yonder’s solutions are trusted by global brands like Henkel and Silk Logistics, and its commitment to innovation continues to drive digital transformation in warehouse and supply chain management.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/smart-warehousing-market-199732421.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smart Warehousing Market to Witness Notable Growth Analysis, Opportunities, and Future Scope Forecast 2030